Pipeline-in-a-drug, page-23

Spot on, I think the recent board changes resulted in the market taking their eye off the ball for a while. [To be expected] We can now concentrate on watching the parts fall into place over the coming weeks. By the end of the month is not out of the question. [In terms of the Phase 2/3 adaptive registration trial.]

So pull up a chair, sit back and watch the show unfold. What has happened over the last 12 months is really quite amazing, for those who haven't done so, go back and compare today's Pharmaust, with a new energized board, still reasonably new CEO complete with a COO, CSO, production/Quality manager and head of Manufacturing compared to 12months ago.

Then top that off with stunning results from the Phase 1/2 MEND trial, Orphan Drug Designation and today's Open Label Study update.

Funding is always a challenge, but it will occur, we just don't know the details yet. There are so many moving parts, its hard to speculate on what its composition may look like. Maybe something from left field ??


Cheers